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background
 
Pilot studies suggest that a single, 2-g oral dose of azithromycin may be an alternative
to a 2.4-MU intramuscular dose of penicillin G benzathine in the prevention and treat-
ment of syphilis. We evaluated the efficacy of treatment with azithromycin in a develop-
ing country.
 
methods
 
A total of 328 subjects, 25 with primary and 303 with high-titer (a titer of at least 1:8 on
a rapid plasmin reagin [RPR] test) latent syphilis, were recruited through screening of
high-risk populations in Mbeya, Tanzania, and randomly assigned to receive 2 g of az-
ithromycin orally (163 subjects) or 2.4 million units of penicillin G benzathine intra-
muscularly (165 subjects). The primary outcome was treatment efficacy, with cure de-
fined serologically (a decline in the RPR titer of at least two dilutions by nine months
after treatment) and, in primary syphilis, by epithelialization of ulcers within one or
two weeks.
 
results
 
The average age of participants was 27.0 years, 235 (71.6 percent) were female, and
171 (52.1 percent) were seropositive for human immunodeficiency virus. Cure rates
were 97.7 percent (95 percent confidence interval, 94.0 to 99.4) in the azithromycin
group and 95.0 percent (95 percent confidence interval, 90.6 to 97.8) in the penicillin G
benzathine group (95 percent confidence interval for the difference, ¡1.7 to 7.1 percent),
achieving prespecified criteria for equivalence. Cure rates were also similar three and
six months after treatment in the two groups and in all subgroups. Cure rates at three
months were 59.4 percent (95 percent confidence interval, 51.8 to 67.1) in the azithro-
mycin group and 59.5 percent (95 percent confidence interval, 51.8 to 67.3) in the pen-
icillin G benzathine group and at six months were 85.5 percent (95 percent confidence
interval, 79.4 to 90.6) and 81.5 percent (95 percent confidence interval, 74.8 to 87.4),
respectively.
 
conclusions
 
Single-dose oral azithromycin is effective in treating syphilis and may be particularly
useful in developing countries in which the use of penicillin G benzathine injections is
problematic. However, recent reports of azithromycin-resistant 
 
Treponema pallidum
 
 in
the United States indicate the importance of continued monitoring for resistance.
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single intramuscular injection
 
of 2.4 million units (MU) of penicillin G
benzathine is the recommended therapy
for early syphilis.
 
1
 
 Major advantages of this regimen
are its low cost and absence of problems related
to poor adherence, whereas disadvantages include
pain associated with large-volume (4 ml), deep, in-
tramuscular injections; the relatively high preva-
lence of self-reported penicillin allergy in some set-
tings; and the need for injection equipment and
medically trained personnel, which may be lacking
in countries with few health resources. In addition,
there are risks of transmission of blood-borne in-
fections, such as human immunodeficiency virus
(HIV), if injection equipment is reused.
The availability of an effective, well-tolerated,
oral, single-dose therapy would overcome the dis-
advantages associated with injectable penicillin
G benzathine. Azithromycin, a macrolide antibiotic
with a long (68 hours) half-life in tissue and prov-
en efficacy against 
 
Chlamydia trachomatis,
 
2
 
 
 
Neisseria
gonorrhoeae,
 
3
 
 and 
 
Haemophilus ducreyi,
 
4
 
 is a promising
candidate. The results of two pilot studies suggest-
ed that the drug may be effective in preventing syph-
ilis in persons exposed to patients with infectious
cases
 
5
 
 and in treating early syphilis.
 
6
 
 Expanding on
these small pilot studies in the United States, we
present the results of a randomized, controlled tri-
al conducted in a developing country to test the hy-
pothesis that the efficacy of a single, 2-g oral dose
of azithromycin is equivalent to that of standard
treatment with 2.4 MU of penicillin G benzathine
for the treatment of early syphilis.
The study protocol was approved by the ethics com-
mittees of the Tanzanian National Institute for Med-
ical Research and the London School of Hygiene
and Tropical Medicine. The study was conducted
in collaboration with the Mbeya Medical Research
Programme. Pfizer donated 250 doses of azithro-
mycin but had no other involvement in the study.
 
participants
 
Persons with confirmed early symptomatic syphi-
lis (primary or secondary) or high-titer latent syph-
ilis were recruited through screening of high-risk
populations in Mbeya Region, Tanzania, including
a cohort of female bar workers, patients with sex-
ually transmitted infections attending four public
clinics, and traditional-brew sellers participating
in a screening and treatment intervention for sexu-
ally transmitted infections. As part of intervention
activities for sexually transmitted infections, per-
sons from these three groups were examined for
clinical and serologic signs of syphilis. 
Persons with presumptive primary or secondary
syphilis and those with a reactive rapid plasma rea-
gin (RPR) test (VD25, Murex Diagnostics) at the
time of screening were eligible for the study. Addi-
tional eligibility criteria included an age of at least
18 years and residence in Mbeya. Exclusion criteria
were pregnancy, known allergy to penicillin or mac-
rolide antibiotics, use of antibiotics active against
syphilis during the preceding six months for symp-
tomatic cases or during the preceding two years for
asymptomatic cases, and concurrent illnesses re-
quiring treatment with antibiotics effective against
syphilis. 
Eligible participants were informed of the study’s
aims, procedures, and associated risks and provid-
ed written informed consent and a blood sample.
On the following day, RPR tests were repeated and
 
Treponema pallidum
 
 particle agglutination tests (Se-
rodia, Fujirebio) were performed on blood samples
at the research laboratory of the Mbeya Medical Re-
search Programme in Mbeya. As planned before
the start of the study, if RPR titers were found to be
1:4 or less or the 
 
T. pallidum
 
 particle agglutination
test was nonreactive, participants were retrospec-
tively excluded from the trial unless primary syphi-
lis was confirmed by the finding of 
 
T. pallidum
 
 in ul-
cer exudates on polymerase chain reaction (PCR).
 
7
 
 
Among eligible participants, HIV serologic sta-
tus was determined through a dual enzyme-linked
immunosorbent assay (Determine HIV 1/2, Abbott,
and Enzygnost HIV 1/2 plus, Behring) of samples.
All consenting subjects were offered counseling
before and after undergoing tests for HIV. Eligible
HIV-infected participants received cotrimoxazole
prophylaxis and were referred to existing support
services in Mbeya, through which further treatment
of opportunistic infections was available. The study
was conducted between September 2000 and Sep-
tember 2003.
 
definitions
 
Primary and secondary syphilis were defined by the
presence of genital ulcers or condylomata lata, re-
spectively, confirmed to be positive for 
 
T. pallidum
 
on PCR. High-titer latent syphilis was defined on
the basis of a reactive 
 
T. pallidum
 
 particle agglutina-
tion test and an RPR titer of at least 1:8 in the ab-
a
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sence of ulcers or condylomata lata confirmed to
be positive for 
 
T. pallidum
 
 on PCR.
The primary outcome was serologic cure, defined
as a decrease in the RPR titer by at least two dilu-
tions before or at the nine-month follow-up exami-
nation, with the titer at the time of treatment used
as the baseline. In the case of primary and second-
ary syphilis, complete resolution or improvement
(epithelialization in progress) of lesions within
one or two weeks after treatment was also required.
Secondary outcomes were cure rates three and six
months after treatment and cure rates according to
age, sex, stage of syphilis, and RPR titer at treat-
ment. Treatment was considered to have failed if
the RPR titer increased by two or more dilutions as
compared with the baseline titer before cure or if
the titer had not declined by at least two dilutions
within nine months. Participants discontinued their
participation in the study once cured. Thus, increas-
es in titers after cure, possibly indicating relapse
or reinfection, would not be identified. Before dis-
charging participants from the study, we deter-
mined all titers in parallel using stored specimens,
to avoid any error resulting from testing of unpaired
specimens.
 
randomization and follow-up
 
A random allocation schedule, stratified according
to study group, was generated centrally with the use
of blocked randomization, random permuted blocks
of four, and a 1:1 allocation ratio. The allocation
was concealed from investigators through the use
of sequentially numbered, sealed envelopes.
Participants with primary syphilis were reex-
amined one or two weeks after treatment to assess
whether syphilitic lesions had resolved. All partici-
pants were reassessed every three months for up to
nine months until they were cured. At each follow-
up examination, participants reported any sexual
exposure between visits and were clinically evaluat-
ed for persistent or recurrent syphilis. A 5-ml blood
sample was obtained for serologic analysis for syph-
ilis. Laboratory technicians were unaware of partic-
ipants’ treatment allocation, treatment response,
and previous RPR test results at all times. All RPR
tests were carried out in duplicate by two indepen-
dent technicians, and tests were repeated in cases
of discrepant results.
 
statistical analysis
 
In this equivalence trial, we estimated that at least
133 participants were required in each group for
the study to have a statistical power of 80 percent to
exclude the possibility that the absolute efficacy of
azithromycin was at least 7.5 percent less than that
of penicillin (with a one-sided P<0.05), assuming
that the true efficacy of each agent was equivalent
at 95 percent and that approximately 30 percent of
participants would be lost to follow-up. 
A primary analysis was carried out to estimate
cure rates at or before the three-, six-, and nine-
month follow-up visit with the use of Kaplan–Mei-
er methods. Data on participants who were lost to
follow-up before being cured were censored on the
date of the last follow-up visit. Differences between
groups in the cure rates at nine months were as-
sessed with the use of an approximate z-test after
complementary log-log transformation, whereas
overall differences in the time to cure between
groups were assessed with the use of the log-rank
test. Since participants did not always attend their
scheduled appointments on time, a secondary analy-
sis was performed based on exact times from treat-
ment to follow-up visits with the use of the Kaplan–
Meier method. In this analysis, cure was assumed to
have occurred at the midpoint between two succes-
sive examinations. On the basis of the secondary
analysis (exact follow-up times), significant deter-
minants of cure were included in a Cox regression
model to examine their joint effect on cure rates.
Two-sided tests were used throughout. All statisti-
cal analyses were carried out with the use of Stata
software (version 8).
From September 2000 to March 2003, 6308 eligi-
bility assessments were performed. Of 628 persons
recruited on site, 300 were retrospectively found
to be ineligible on the basis of serologic results for
syphilis at the reference laboratory (Fig. 1). Thus,
328 persons fulfilled the inclusion criteria: 65 fe-
male bar workers, 149 attendees of a sexually trans-
mitted infection clinic, and 114 traditional-brew
sellers. Of these 328 participants, 165 (50.3 percent)
received penicillin G benzathine and 163 (49.7 per-
cent) azithromycin (Zithromax, Pfizer).
The average age of participants was 27.0 years
(range, 15 to 60), 235 (71.6 percent) were female,
and 171 (52.1 percent) were seropositive for HIV
(Table 1). Twelve participants were younger than
18 years of age, having misreported their age at the
time of recruitment, but were included in the analy-
sis. Primary syphilis was confirmed by PCR in 25
results
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(7.6 percent) participants. There were no PCR-con-
firmed cases of secondary syphilis. The RPR titer
was no more than 1:32 in 217 (66.2 percent) partic-
ipants and at least 1:64 in 111 (33.8 percent). The
two treatment groups were generally similar with
regard to sociodemographic, behavioral, and bio-
logic characteristics (Table 1).
Of the 328 participants, 31 (9.5 percent) were
lost to follow-up, including 20 (6.1 percent) who
did not attend any follow-up visits and who were
excluded from the analysis of cure rates. An addi-
tional 11 participants (3.4 percent), 6 in the azith-
romycin group and 5 in the penicillin G benza-
thine group, were lost after the first follow-up visit.
Four of these (two in each group) were excluded
after having been re-treated for presumptive symp-
tomatic reinfection or relapse (ulcers or rash). PCR
testing of these lesions was not performed, but se-
rologic analysis was not suggestive of relapse or
reinfection, since RPR titers showed no increase.
Among those treated with azithromycin, 140 par-
ticipants were interviewed about adverse events at
the first follow-up visit. A total of 12 reported nau-
sea (8.6 percent), 6 stomach pain (4.3 percent), 1 di-
arrhea (0.7 percent), and 1 vomiting (0.7 percent).
Among the 24 of 25 participants with confirmed
primary syphilis who were examined one or two
weeks after treatment, ulcers had resolved in 15
(62.5 percent) and were in the process of healing in
9 (37.5 percent). There was no significant differ-
 
Figure 1. Enrollment and Outcomes.
6308 Assessed for eligibility
(RPR test performed on site)
628 Enrolled and underwent
randomization on site
5680 Were ineligible
5666 Did not meet inclusion
         criteria
    14 Declined to participate
315 Assigned to 2.4 MU  
of penicillin G benzathine
intramuscularly
313 Assigned to 2 g  
of azithromycin orally
150 Ineligible on basis of serologic
results for syphilis at research
laboratory (RPR test nonreactive
or RPR titer ≤1:4)
165 Included 163 Included
12 Lost to follow-up (did not
attend any follow-up examination)
8 Lost to follow-up (did not
attend any follow-up examination)
153 Analyzed 155 Analyzed
150 Ineligible on basis of serologic
results for syphilis at research
laboratory (RPR test nonreactive
or RPR titer ≤1:4)
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ence in these rates between groups. At the three-
month follow-up examination, all ulcers had com-
pletely resolved.
Cure was recorded at or before the nine-month
follow-up visit in all but 21 participants. Data on
9 participants were censored at the three-month
follow-up visit and on 2 at the six-month follow-up
visit, and treatment failure was recorded in 10 par-
ticipants at the nine-month follow-up visit. In the
primary analysis, the cure rates were 97.7 percent
(95 percent confidence interval, 94.0 to 99.4) in the
azithromycin group and 95.0 percent (95 percent
confidence interval, 90.6 to 97.8) in the penicillin
G benzathine group (95 percent confidence inter-
val for the difference, ¡1.7 to 7.1 percent), achiev-
ing prespecified criteria for equivalence and indi-
cating that the possibility that a cure rate that was
7.5 percentage points lower for azithromycin than
for penicillin G benzathine could be confidently
excluded (z=3.09, P<0.002) (Table 2). Cure rates at
the three-month follow-up visit were 59.4 percent
(95 percent confidence interval, 51.8 to 67.1) in the
azithromycin group and 59.5 percent (95 percent
confidence interval, 51.8 to 67.3) in the penicillin
G benzathine group, and cure rates at the six-month
follow-up were 85.5 percent (95 percent confidence
interval, 79.4 to 90.6) and 81.5 percent (95 percent
confidence interval, 74.8 to 87.4), respectively (Ta-
ble 2 and Fig. 2). Consistent findings were obtained
in subgroup analyses based on study group, stage
of syphilis, baseline RPR titer, and HIV status (Ta-
ble 2) and age and sex (data not shown), with azith-
romycin showing equal or greater efficacy in all sub-
groups examined.
Since there was substantial variation between
participants in the timing of follow-up visits, with
ranges from 32 to 133 days for the 3-month visit,
130 to 229 days for the 6-month visit, and 207 to 304
days for the 9-month visit, we conducted a second-
ary analysis that was based on the exact intervals
between treatment and follow-up examinations.
The findings were similar, with a cure rate at nine
months of 98.3 percent (95 percent confidence in-
terval, 94.5 to 99.7) in the azithromycin group and
96.5 percent (95 percent confidence interval, 92.0
to 98.8) in the penicillin G benzathine group.
Subgroup analyses were also used to identify
sociodemographic and biologic determinants of
cure rates in the two groups. Neither age nor sex
was significantly associated with cure rates. Surviv-
al curves for the time to cure on the basis of the sec-
ondary analysis in selected subgroups are shown in
Figure 3. The time between treatment and cure was
shorter among participants with primary syphilis
than among those with latent cases (Fig. 3B) and
among participants with RPR titers of at least 1:64
than among those with lower titers (Fig. 3C), al-
though the cure rates by nine months were high in
all subgroups. HIV status had no consistent effect
on cure rates. At nine months, the cure rate was
94.7 percent (95 percent confidence interval, 90.4
to 97.5) among HIV-positive participants and 98.4
percent (95 percent confidence interval, 94.8 to 99.7)
among HIV-negative participants (P>0.5) (Fig. 3D).
In a Cox regression model including baseline
RPR titer and syphilis stage, the adjusted hazard ra-
tio (based on time to cure) for treatment with azith-
romycin, as compared with treatment with penicil-
 
* Values were missing for four subjects in the penicillin group and three in the 
 
azithromycin group.
 
Table 1. Baseline Characteristics.
Characteristic
Penicillin G 
Benzathine
(N=165)
Azithromycin
(N=163)
Total
(N=328)
 
number (percent)
 
Study group
Female bar workers 33 (20.0) 32 (19.6) 65 (19.8)
Patients attending a sexually 
transmitted infection clinic
71 (43.0) 78 (47.9) 149 (45.4)
Traditional-brew sellers 61 (37.0) 53 (32.5) 114 (34.8)
Sex
Male 41 (24.8) 52 (31.9) 93 (28.4)
Female 124 (75.2) 111 (68.1) 235 (71.6)
Age
15–24 yr 77 (46.7) 69 (42.3) 146 (44.5)
≥25 yr 88 (53.3) 94 (57.7) 182 (55.5)
No. of sexual partners in past 3 mo*
≤1 121 (75.2) 110 (68.8) 231 (72.0)
≥2 40 (24.8) 50 (31.2) 90 (28.0)
HIV status
Negative 78 (47.3) 79 (48.5) 157 (47.9)
Positive 87 (52.7) 84 (51.5) 171 (52.1)
Syphilis stage
Primary 14 (8.5) 11 (6.7) 25 (7.6)
Latent 151 (91.5) 152 (93.3) 303 (92.4)
RPR titer at treatment
≤1:32 110 (66.7) 107 (65.6) 217 (66.2)
≥1:64 55 (33.3) 56 (34.4) 111 (33.8)
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lin G benzathine, was 1.15 (95 percent confidence
interval, 0.85 to 1.36); that for an RPR titer of at
least 1:64, as compared with a titer of no more than
1:32, was 2.12 (95 percent confidence interval, 1.66
to 2.72); that for primary syphilis, as compared with
latent syphilis, was 1.98 (95 percent confidence in-
terval, 1.30 to 3.01); and that for HIV-positive sta-
tus, as compared with HIV-negative status, was 0.89
(95 percent confidence interval, 0.71 to 1.13).
The treatment efficacy of the two regimens was
equivalent at 97.7 percent (95 percent confidence
interval, 94.0 to 99.4) for azithromycin and 95.0
percent (95 percent confidence interval, 90.6 to 97.8)
for penicillin G benzathine. The 95 percent confi-
dence interval for the difference in cure rates ranged
from –1.7 percent to 7.1 percent in favor of azith-
romycin, indicating that a cure rate for azithromy-
cin that was 7.5 percentage points lower than that
for penicillin G benzathine was very unlikely. In ad-
dition, the cure rates were similar in the two groups
throughout the follow-up period and in subgroups
defined according to sociodemographic and bio-
logic characteristics. Within the limitations of cur-
rent serologic means of identifying cure, we clearly
demonstrated that 2 g of azithromycin is as effec-
tive as 2.4 MU of penicillin G benzathine in treat-
ing early syphilis in this study population.
It is reassuring that no treatment failure was ob-
served among participants with confirmed primary
syphilis. However, a recent report from the Centers
for Disease Control and Prevention of well-docu-
mented treatment failure in three patients treated
with 2 g of azithromycin for primary syphilis and
the detection of a strain of 
 
T. pallidum
 
 with function-
al azithromycin resistance among selected groups
with high-risk sexual behavior in the United States
and Ireland have aroused concern about the effica-
cy of this regimen.
 
8,9
 
 In Mbeya, all cases of primary
syphilis were clinically cured by the three-month
follow-up visit and showed evidence of serologic
cure by the six-month follow-up visit. It is unfortu-
nate that PCR was not performed on specimens
from the nine participants (four treated with azith-
romycin and five with penicillin) whose primary le-
sions had not completely resolved after one or two
weeks, since biologic treatment failures could then
have been verified or ruled out. Our findings do
not suggest that azithromycin-resistant strains of
 
T. pallidum
 
 are widespread in Tanzania at this time,
but the observations from the United States and
Ireland emphasize the importance of ongoing mon-
itoring for drug resistance.
Among the 140 participants who were treated
with azithromycin and interviewed, 11.4 percent re-
ported mild-to-moderate side effects that were pre-
dominantly gastrointestinal. It appears that with
the high, 2-g dose of azithromycin, the frequency
of side effects was no higher than that reported pre-
viously for lower doses.
 
10
 
Previous studies assessing the response of pa-
tients with early syphilis to one 2.4-MU dose of pen-
icillin G benzathine have raised doubts concerning
the effectiveness of this regimen in HIV-infected
patients.
 
11
 
 Our findings do not confirm these ob-
servations. Although there were too few participants
with primary syphilis for us to detect small differ-
ences in efficacy, the cure rate was 100 percent in
the small number of HIV-positive participants with
primary syphilis. The cure rate among all HIV-pos-
itive participants with latent syphilis was, at 92.1
percent, slightly lower than the 98.6 percent re-
sponse among participants without HIV infection,
but this difference was not statistically significant.
It is known that 
 
T. pallidum
 
 frequently invades the
central nervous system in early syphilis and that it
may persist there for months after treatment with-
out causing early signs or symptoms of neurosyph-
ilis even if nontreponemal test titers indicate the
occurrence of a serologic cure,
 
11
 
 and there is con-
cern that HIV-positive patients may be at increased
risk for neurosyphilis.
 
12
 
 Since we did not obtain
cerebrospinal fluid for diagnostic tests, we cannot
definitively rule out this possibility.
discussion
 
Figure 2. Mean Cure Rates. 
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Because it was difficult to obtain reliable medi-
cal histories, we defined early latent syphilis exclu-
sively on the basis of an RPR titer of at least 1:8 in
the absence of syphilitic lesions confirmed to be
positive for 
 
T. pallidum
 
 by PCR. Although RPR titers
are assumed to fall during the course of latent in-
fection, the use of this definition will have intro-
duced some degree of (nondifferential) misclassi-
fication, with the inclusion of some participants
with late latent cases. Our results are therefore ap-
plicable to a mixed population of persons with ear-
ly and latent cases, making them highly relevant to
syphilis-control strategies in developing countries
in which, for example, the duration of infection
is usually unknown in women being screened for
syphilis during antenatal care.
A major problem affecting research on syphilis
treatment is the imprecision of the definition of se-
rologic cure. Such imprecision may have led us ei-
ther to overestimate or to underestimate the true
rates of cure. Since laboratory technicians were un-
aware of participants’ treatment assignments, how-
ever, this should not have biased the comparison of
cure rates in the two groups.
Finally, we could not identify late relapses after
serologic cure, since we essentially did not collect
information on the clinical and serologic history of
participants after they had been cured. The excep-
tion was female bar workers, who were followed as
part of other research activities. Relapse is assumed
to be highly unlikely if a satisfactory decline in the
nontreponemal test titer occurs in the absence of
symptoms and signs of disease and is maintained
for 12 months.
 
13
 
 Since participants were not fol-
lowed once they were cured, however, some may
have had an unrecorded relapse after serologic cure.
In 8 of 65 bar workers participating in the trial, in-
creases in the RPR titer of at least two dilutions were
detected after they were considered serologically
cured. One had an increase in the RPR titer 6 months
after cure, and the rest had increases 9 to 15 months
after cure. Four of these increases in RPR titer oc-
 
Figure 3. Cure Rates According to Treatment (Panel A), Stage of Syphilis (Panel B), RPR Titer at Baseline (Panel C), and HIV Status (Panel D).
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curred among the 15 HIV-negative bar workers
and 4 among the 50 HIV-positive bar workers. It is
likely that some or all of the increases in RPR titer
in this highly exposed group were due to reinfec-
tion. If one assumes that all were due to relapse, the
proportions with a relapse more than nine months
after treatment were 12.5 percent (95 percent con-
fidence interval, 3.5 to 29.0) in the azithromycin
group and 12.1 percent (95 percent confidence in-
terval, 3.4 to 28.2) in the penicillin G benzathine
group. On the basis of these limited data, therefore,
there is no indication that the relapse rate was high-
er in either group. However, a definitive answer to
this question would require long-term follow-up
of a lower-risk study population in which reinfec-
tions are less likely.
In conclusion, this randomized, controlled trial
has provided clear evidence that a single, 2-g dose
of azithromycin is as effective as a 2.4-MU dose of
penicillin G benzathine for the treatment of early
syphilis. Although continued monitoring for azith-
romycin resistance will be essential, given the logis-
tical advantages conferred by this oral treatment,
particularly in resource-poor settings in develop-
ing countries, and the efficacy of azithromycin in
treating other common sexually transmitted infec-
tions that may be present with syphilis as mixed in-
fections, our findings support the wider use of this
alternative regimen in syphilis-control programs.
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